![image2](https://www.med.unc.edu/genetherapy/wp-content/uploads/sites/811/2018/10/aravind-asokans-gene-therapy-gene-therapy-for-duchenne-muscular-dystrophy-teamwork-with-duke-image2.jpeg)
The collaboration between Aravind Asokan, researcher at the Gene Therapy Center, and Charles Gersbach, a Duke biomedical engineer, to develop gene therapy for Duchenne Muscular Dystrophy – a rapidly worsening form of muscular dystrophy – is spotlighted on UNC’s website March 6.
Dr. Asokan’s expertise is in gene delivery. Dr. Gersbach’s background is in genome editing. Together they hope to modify DNA sequences to correct disease-causing mutations.